{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:11:56Z","timestamp":1792012316183,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41375-025-02634-2","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T14:12:43Z","timestamp":1746799963000},"page":"1640-1649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangements"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-2745","authenticated-orcid":false,"given":"Alex","family":"Bataller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1945-2571","authenticated-orcid":false,"given":"Hannah E.","family":"Goulart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bazinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-4249","authenticated-orcid":false,"given":"Ian M.","family":"Bouligny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-2567","authenticated-orcid":false,"given":"Jayastu","family":"Senapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-8485","authenticated-orcid":false,"given":"Fadi G.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-6453","authenticated-orcid":false,"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-4895","authenticated-orcid":false,"given":"Musa","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4533-5176","authenticated-orcid":false,"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9482-4806","authenticated-orcid":false,"given":"Guiling","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"2634_CR1","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrc2253","volume":"7","author":"AV Krivtsov","year":"2007","unstructured":"Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7:823\u201333.","journal-title":"Nat Rev Cancer"},{"key":"2634_CR2","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/s41375-024-02261-3","volume":"38","author":"C Meyer","year":"2024","unstructured":"Meyer C, Larghero P, Lopes BA, Marschalek R. The KMT2A\/MLL consensus gene structure: a comprehensive update for research and diagnostic implications. Leukemia. 2024;38:1403\u20136.","journal-title":"Leukemia"},{"key":"2634_CR3","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","volume":"37","author":"C Meyer","year":"2023","unstructured":"Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gr\u00f6ger D, Sutton R, et al. The KMT2A recombinome of acute leukemias in 2023. Leukemia. 2023;37:988\u20131005. 2023\/05\/01.","journal-title":"Leukemia"},{"key":"2634_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2634_CR5","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","volume":"92","author":"D Grimwade","year":"1998","unstructured":"Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322\u201333.","journal-title":"Blood"},{"key":"2634_CR6","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","volume":"100","author":"JC Byrd","year":"2002","unstructured":"Byrd JC, Mro\u0301zek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325\u201336.","journal-title":"Blood"},{"key":"2634_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","volume":"43","author":"GC Issa","year":"2024","unstructured":"Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, et al. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol. 2024;43:75\u201384.","journal-title":"J Clin Oncol"},{"key":"2634_CR8","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","volume":"615","author":"GC Issa","year":"2023","unstructured":"Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615:920\u20134.","journal-title":"Nature"},{"key":"2634_CR9","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","volume":"25","author":"ES Wang","year":"2024","unstructured":"Wang ES, Issa GC, Erba HP, Altman JK, Montesinos P, DeBotton S, et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol. 2024;25:1310\u201324.","journal-title":"Lancet Oncol"},{"key":"2634_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1182\/blood-2023-172422","volume":"142","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Searle E, Abdul-Hay M, Abedin S, Aldoss I, Alfonso Pi\u00e9rola A, et al. A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed\/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations. Blood. 2023;142:57\u201357.","journal-title":"Blood"},{"key":"2634_CR11","doi-asserted-by":"publisher","first-page":"TPS7064","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7064","volume":"40","author":"F Ravandi","year":"2022","unstructured":"Ravandi F, Kishtagari A, Carraway HE, Schiller GJ, Morris S, Cacovean A, et al. COVALENT-101: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed\/refractory (R\/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM). J Clin Oncol. 2022;40:TPS7064\u2013TPS7064.","journal-title":"J Clin Oncol"},{"key":"2634_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354\u201366.","journal-title":"Blood"},{"key":"2634_CR13","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/leu.2012.319","volume":"27","author":"Y Chen","year":"2013","unstructured":"Chen Y, Kantarjian H, Pierce S, Faderl S, O\u2019Brien S, Qiao W, et al. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013;27:836\u201342.","journal-title":"Leukemia"},{"key":"2634_CR14","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1182\/blood-2003-02-0434","volume":"102","author":"C Schoch","year":"2003","unstructured":"Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23\/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003;102:2395\u2013402.","journal-title":"Blood"},{"key":"2634_CR15","doi-asserted-by":"publisher","first-page":"26340","DOI":"10.1073\/pnas.2014732117","volume":"117","author":"M Bill","year":"2020","unstructured":"Bill M, Mr\u00f3zek K, Kohlschmidt J, Eisfeld A-K, Walker CJ, Nicolet D, et al. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23\/KMT2A. Proc Natl Acad Sci. 2020;117:26340\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"2634_CR16","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.2008.16.7981","volume":"27","author":"J Krauter","year":"2009","unstructured":"Krauter J, Wagner K, Sch\u00e4fer I, Marschalek R, Meyer C, Heil G, et al. Prognostic Factors in Adult Patients up to 60 Years Old With Acute Myeloid Leukemia and Translocations of Chromosome Band 11q23: Individual Patient Data\u2013Based Meta-Analysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2009;27:3000\u20136.","journal-title":"J Clin Oncol"},{"key":"2634_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00557-6","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021;11:162.","journal-title":"Blood Cancer J"},{"key":"2634_CR18","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/s41375-024-02333-4","volume":"38","author":"A Hern\u00e1ndez-S\u00e1nchez","year":"2024","unstructured":"Hern\u00e1ndez-S\u00e1nchez A, Gonz\u00e1lez T, Sobas M, Str\u00e4ng E, Castellani G, Ab\u00e1igar M, et al. Rearrangements involving 11q23.3\/KMT2A in adult AML: mutational landscape and prognostic implications \u2013 a HARMONY study. Leukemia. 2024;38:1929\u201337.","journal-title":"Leukemia"},{"key":"2634_CR19","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1182\/blood.V82.12.3705.3705","volume":"82","author":"HJ Gill Super","year":"1993","unstructured":"Gill Super HJ, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J, et al. Rearrangements of the MLL Gene in Therapy-Related Acute Myeloid Leukemia in Patients Previously Treated With Agents Targeting DNA-Topoisomerase II. Blood. 1993;82:3705\u201311.","journal-title":"Blood"},{"key":"2634_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"2634_CR21","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.clml.2021.05.016","volume":"21","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Short NJ, Fathi AT, Marcucci G, Ravandi F, Tallman M, et al. Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. Clin Lymphoma Myeloma Leuk. 2021;21:580\u201397.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2634_CR22","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1182\/blood-2024-201097","volume":"144","author":"J Othman","year":"2024","unstructured":"Othman J, Potter N, Freeman SD, McCarthy N, Jovanovic J, Runglall M, et al. Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements - Experience from UK NCRI AML17 and AML19. Blood. 2024;144:845 2024\/11\/05\/.","journal-title":"Blood"},{"key":"2634_CR23","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood.V90.11.4532","volume":"90","author":"K Mr\u00f3zek","year":"1997","unstructured":"Mr\u00f3zek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PRK, Rao KW, et al. Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: A Cancer and Leukemia Group B Study. Blood. 1997;90:4532\u20138.","journal-title":"Blood"},{"key":"2634_CR24","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1182\/bloodadvances.2021004580","volume":"5","author":"G Richard-Carpentier","year":"2021","unstructured":"Richard-Carpentier G, Kantarjian HM, Tang G, Yin CC, Khoury JD, Issa GC, et al. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021;5:5415\u20139.","journal-title":"Blood Adv"},{"key":"2634_CR25","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1182\/bloodadvances.2021005585","volume":"6","author":"A Bataller","year":"2022","unstructured":"Bataller A, Garrido A, Guijarro F, O\u00f1ate G, Diaz-Bey\u00e1 M, Arnan M, et al. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Adv. 2022;6:1193\u2013206.","journal-title":"Blood Adv"},{"key":"2634_CR26","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1080\/10428194.2022.2116934","volume":"63","author":"BJ Ball","year":"2022","unstructured":"Ball BJ, Arslan S, Koller P, Ngo D, Afkhami M, Salhotra A, et al. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). Leuk Lymphoma. 2022;63:3232\u20136.","journal-title":"Leuk Lymphoma"},{"key":"2634_CR27","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1182\/blood.2023020102","volume":"142","author":"J Xie","year":"2023","unstructured":"Xie J, Bao X, Xue S-L, Shen H, Cen J, Yao L, et al. Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML. Blood. 2023;142:1323\u20137.","journal-title":"Blood"},{"key":"2634_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3324\/haematol.2020.271619","volume":"107","author":"T Milan","year":"2022","unstructured":"Milan T, Celton M, Lagac\u00e9 K, Roques \u00c9, Safa-Tahar-Henni S, Bresson E, et al. Epigenetic changes in human model KMT2A leukemias highlight early events during leukemogenesis. Haematologica. 2022;107:86\u201399.","journal-title":"Haematologica"},{"key":"2634_CR29","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1182\/blood-2016-10-691428","volume":"129","author":"TA Milne","year":"2017","unstructured":"Milne TA. Mouse models of MLL leukemia: recapitulating the human disease. Blood. 2017;129:2217\u201323.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02634-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02634-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02634-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T02:05:27Z","timestamp":1751249127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02634-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2634"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02634-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ghayas C. Issa reports consulting or advisory role for Novartis, Kura Oncology, Syndax, NuProbe, AbbVie and Sanofi, and research funding from Novartis, Syndax, Kura Oncology, Merck, Cullinan Oncology, Astex Pharmaceuticals and NuProbe. Courtney D. DiNardo has been a board of directors or advisory committee member for Genmab, GSK, Kura Oncology, and Notable Labs; has received honoraria from Kura, Astellas Pharma, Bluebird Bio, Bristol-Myers Squibb, Foghorn Therapeutics, Immune-Onc Therapeutics, Novartis, Takeda Oncology, Gilead Sciences, and Jazz Pharmaceuticals; is a current holder of stock options for Notable Labs; has been a consultant for AbbVie and Servier; and has received research funding from Servier, Bristol-Myers Squibb, Foghorn, Immune-Onc Therapeutics, Loxo Oncology, Astex Pharmaceuticals, Cleave, and Forma. Naval G. Daver has received research funding from Astellas Pharma, AbbVie, Genentech, Daiichi Sankyo, Gilead Sciences, ImmunoGen, Pfizer, Bristol Myers Squibb, Trovagene, Servier, Novimmune, Incyte, Hanmi Pharm, Fate Therapeutics, Amgen, Kite Pharma, Novartis, Astex Pharmaceuticals, KAHR, Shattuck, Sobi, GlycoMimetics, and Trillium; has been an advisor for Astellas Pharma, AbbVie, Genentech, Daiichi Sankyo, Novartis, Jazz Pharmaceuticals, Amgen, Servier, Karyopharm Therapeutics, Trovagene, Trillium, Syndax, Gilead Sciences, Pfizer, Bristol Myers Squibb, Kite Pharma, Actinium Pharmaceuticals, Arog Pharmaceuticals, ImmunoGen, Arcellx, and Shattuck; has been a data monitoring committee member for Kartos Therapeutics and Jazz Pharmaceuticals; has been a consultant or board of directors or advisory committee member for Agios, Celgene, Sobi, and STAR Therapeutics; and has received research funding from Karyopham Therapeutics and Newave Pharmaceutical. Tapan M. Kadia has been a consultant for AbbVie, Agios, BMS, Genentech, Jazz Pharmaceuticals, Novartis, Servier, and PinotBio; has received research funding from AbbVie, BMS, Genentech, Jazz Pharmaceuticals, Pfizer, Cellenkos, Ascentage Pharma, GenFleet Therapeutics, Astellas Pharma, AstraZeneca, Amgen, Cyclacel Pharmaceuticals, Delta-Fly Pharma, Iterion Therapeutics, GlycoMimetics, and Regeneron Pharmaceuticals; and has received honoraria from Astex Pharmaceuticals. Gautam Borthakur has received research funding from Astex Pharmaceuticals, Ryvu Therapeutics, and PTC Therapeutics; has been a board of directors or advisory committee member for Pacyclex Pharmaceuticals, Novartis, CytomX, and Bio Ascend; and has been a consultant for Catamaran Bio, AbbVie, PPD Development, Protagonist Therapeutics, and Janssen. Koji Sasaki reports fees for professional activities from Amgen, Chugai Pharmaceutical, Daiichi Sankyo Company, Novartis, Otsuka Pharmaceutical Co., Ltd., and Pfizer. Kelly Chien declares honoraria from Otsuka Pharma, and consultancy fee from Pfizer Japan. Nicholas J. Short has been a consultant for Takeda Oncology, AstraZeneca, Amgen, Novartis, and Pfizer and received research funding from Takeda Oncology, Astellas, and Stemline Therapeutics as well as honoraria from Amgen. Musa Yilmaz has received research funding from Daiichi-Sankyo and Pfizer. Guillermo Garcia-Manero has received research funding from Astex Pharmaceuticals, Novartis, AbbVie, BMS, Genentech, Aprea Therapeutics, Curis, and Gilead Sciences; has been a consultant for Astex Pharmaceuticals, Acceleron Pharma, and BMS; and has received honoraria from Astex Pharmaceuticals, Acceleron Pharma, AbbVie, Novartis, Gilead Sciences, Curis, Genentech, and BMS. Farhad Ravandi has received research funding from Amgen, Astex Pharmaceuticals\/Taiho Oncology, BMS\/Celgene, Syos, AbbVie, Prelude, Xencor, Astellas Pharma, and Biomea Fusion as well as honoraria from Amgen, BMS\/Celgene, Syos, AbbVie, and Astellas Pharma; has been a board of directors or advisory committee member for Astex Pharmaceuticals\/Taiho Oncology; and has been a consultant forBMS\/Celgene, Syos, Novartis, AbbVie, AstraZeneca, and Astellas Pharma. Hagop M. Kantarjian has received research funding from AbbVie, Amgen, Ascentage Pharma, BMS, Daiichi Sankyo, ImmunoGen, Jazz Pharmaceuticals, and Novartis as well as honoraria from AbbVie, Amgen, Amphista Therapeutics, Ascentage Pharma, Astellas Pharma, Biologix, Curis, Ipsen, KAHR, Novartis, Pfizer, Precision Biosciences, Shenzhen TargetRx, and Takeda Oncology. Elias Jabbour has been a consultant for AbbVie, Adaptive Biotechnologies, Amgen, Bristol-Myers Squibb, Novartis, Pfizer Canada Inc, and Takeda Onc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}